Human gastrin- releasing peptide receptor expression in women with uterine cervix cancer.

Charles A. Kunos,Denise Fabian,Dana Napier, Mark S. Stonecypher, Ravyn M. Duncan,Jason Hurt

Frontiers in oncology(2023)

Cited 0|Views5
No score
Abstract
The frequency of overexpression in this study suggests that Pb-DOTAM-GRPR1 radiopharmaceutical treatment may be useful in the management of persistent, recurrent, or metastatic uterine cervix cancer patients. A phase I clinical trial involving patients with metastatic uterine cervix cancer is currently underway (NCT05283330).
More
Translated text
Key words
cervical cancer,gastrin-releasing peptide (GRP) receptor,radiopharmaceutical,uterine cervix adenocarcinoma,uterine cervix cancer
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined